Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
about
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerIn vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathwaysDll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.Eph receptors and ephrins: therapeutic opportunities.Targeted endometrial cancer therapy as a future prospect.pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
P2860
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
@en
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
@nl
type
label
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
@en
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
@nl
prefLabel
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
@en
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
@nl
P2093
P2860
P1476
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
@en
P2093
Anil K Sood
Robert L Coleman
P2860
P304
P356
10.2174/138161212800626201
P577
2012-01-01T00:00:00Z